Viroclinics Biosciences expands with Clinical Trial Operations Services
To provide better support for the pharmaceutical, biotechnology, and medical device industries, Viroclinics has started a specialized group for clinical trial operations.
To provide better support for the pharmaceutical, biotechnology, and medical device industries, Viroclinics has started a specialized group for clinical trial operations. Activities involve preparation of virology sampling kits, on-site sampling handling instruction, courier transport, sample tracking and tracing, and management of sample processing labs. For a smooth logistical flow of samples from all over the globe, Viroclinics works together with sites in Europe, Russia, Ukraine, Australia, New Zealand, USA, Canada, Mexico, Central America region (e.g., Guatemala, El Salvador), South America (Brazil, Argentina, Colombia, Peru, Chile) and South Africa.
The company is demonstrating its sample kits at the InfectiousDisease Week 2013 conference this week in San Francisco.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
